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A B S T R A C T
Since a signiﬁcant proportion of diabetic patients have clinical or subclinical neuropathy, there may be concerns
about the use of local anaesthetics. The present study was designed to determine and compare the eﬀects of
articaine, a widely used anaesthetic in dental practice, and lidocaine on the resting and axonal stimulation-
evoked release of [3H]noradrenaline ([3H]NA) in prefrontal cortex slices and the release of [3H]NA in spinal cord
slices prepared from non-diabetic and streptozocin (STZ)-induced diabetic (glucose level = 22.03 ± 2.31
mmol/l) rats. The peak of allodynia was achieved 9 weeks after STZ-treatment. Articaine and lidocaine inhibited
the stimulation-evoked release in a concentration-dependent manner and increased the resting release by two to
six times. These eﬀects indicate an inhibitory action of these anaesthetics on Na+- and K+-channels. There was
no diﬀerence in clinically important nerve conduction between non-diabetic and diabetic rats, as measured by
the release of transmitter in response to axonal stimulation. The uptake and resting release of NA was sig-
niﬁcantly higher in the brain slices prepared from diabetic rats, but there were no diﬀerences in the spinal cord.
For the adverse eﬀects, the eﬀects of articaine on K+ channels (resting release) are more pronounced compared
to lidocaine. In this respect, articaine has a thiophene ring with high lipid solubility, which may present potential
risks for some patients.
1. Introduction
Diabetes mellitus (DM) is characterized by hyperglycaemia that is
induced by defects in insulin secretion from pancreatic β-cells and/or
the eﬀects of insulin on target cells. After cardiovascular disease, DM is
the third leading cause of death in the US, Europe (Veves et al., 2008)
and Hungary (Jermendy et al., 2016; Vegh et al., 2017). It has been
shown that the risk of neurotoxicity is higher in patients with diabetic
peripheral neuropathy, which is a critical ﬁnding for clinicians who are
involved in dental care or who apply local anaesthetics for surgery or
for short- and long-term pain management.
All local anaesthetics that can inhibit both Na+ and K+-channels
(Scholz, 2002) are potentially neurotoxic, as is the case for articaine
(Bachmann et al., 2012b; Borchard and Drouin, 1980), which is a
widely used anaesthetic in dental care (Snoeck, 2012). The inhibitory
eﬀects of these anaesthetics on Na+ channels are responsible for the
local anaesthetic eﬀect (Karoly et al., 2010; Lenkey et al., 2011; Lenkey
et al., 2010), whereas the inhibition of K+ channels leads to adverse
(Wolﬀ et al., 2014) eﬀects. Patients with diabetes may have peripheral
neuropathy, which may have clinical implications for the use of re-
gional nerve blocks. There is agreement among researchers that the
prevalence and severity of periodontal diseases are greater in in-
dividuals with diabetes (Miley and Terezhalmy, 2005; Santos-Paul
et al., 2015). Therefore, it is essential to be familiar with the possible
complications that may occur during the treatment of diabetic patients.
Articaine is similar to lidocaine, and its use in clinical practice has
shown that it is suitable and safe for clinical interventions that require a
short duration and fast onset of action in dental practice and ambula-
tory spinal anaesthesia (Bachmann et al., 2012a; Snoeck, 2012). Al-
though it has been shown that the risk of neurotoxicity with local
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anaesthetics is relatively small, there are still concerns about the safety
of their use (Strichartz, 2010; Sircuta et al., 2016), especially among
diabetic patients (Kroin et al., 2012).
In previous studies (Borbely et al., 2017; Sircuta et al., 2016), we
showed that lidocaine and bupivacaine, due to their actions on Na+
channels, inhibited the release of transmitters from frontal cortex and
spinal cord slices in response to ongoing axonal activity and strongly
enhanced the resting release induced by the inhibitory eﬀects on K+
channels. The eﬀect on Na+ channels was similar to that of te-
trodotoxin, a selective Na+ channel blocker, and the eﬀect on K+
channels was the same as that evoked by 4-aminopyridine, which is a
selective K+ channel blocker (Sircuta et al., 2016). Accordingly, in this
study, we tested the eﬀects of articaine on these two types of release
using cortical and spinal cord slice preparations taken from non-dia-
betic and streptozotocin (STZ)-induced diabetic rats and compared
them with the eﬀects of lidocaine.
2. Materials and methods
2.1. Animals
The experiments were carried out on male Wistar rats (200–300 g
body weight). The rats were kept in cages with a mesh bottom placed
over a metal plate lined with ground corn cob bedding, at room tem-
perature (20 ± 2 °C) with relative humidity (60–70%) and a 12/12 h
light/dark cycle. Rats were fed standard rodent food pellets and water
ad libitum. The animals were housed in the local animal facility of the
Department of Pharmacology and Pharmacotherapy (Semmelweis
University, Budapest, Hungary) under animal housing and experi-
mentation conditions approved by the ethical guidelines set by the
Ethical Board of Semmelweis University, based on EC Directive 86/
609/EEC. Permissions No. PEI/001/276-4/2013. The animals were
sacriﬁced under slight (isoﬂurane) anaesthesia, their brains were
quickly removed, and the prefrontal cortex or spinal cord was dissected.
2.2. Chemicals
All chemicals were obtained from Sigma-Aldrich Inc. (Budapest,
Hungary). The radioactive compounds were purchased from American
Radiolabeled Chemicals Inc. (USA). Lidocaine HCl (MWt. 288.81) and
articaine HCl (MWt. 320.84) were dissolved in Krebs solution.
Streptozotocin was obtained from Sigma Aldrich Inc. (Budapest,
Hungary).
2.3. Streptozotocin (STZ) treatment
An intraperitoneal (i.p.) injection of STZ (60 mg/kg) at 2.5 ml/kg
body weight was given as described previously (Courteix et al., 1993;
Ganda et al., 1976). The STZ solution was made by dissolving 60 mg/
2.5 ml cold distilled water (1–3 °C) in a relatively dark place prior to the
injections and was used within 10 min to avoid any degradation. The
age-matched control rats were injected with an equal volume of cold
distilled water at the same temperature.
2.4. Blood glucose level measurements
Blood glucose level was measured 1 day prior to and 1 week fol-
lowing streptozotocin injection and after animal sacriﬁce on the day of
the experiment. Brieﬂy, the animals were slightly anaesthetized with
3% isoﬂurane in oxygen via a nose cone using a vaporizer (Eickemeyer
Isoﬂo Vaporiser; Eickemeyer Veterinary Equipment Inc.). A small
amount of blood (50 μl) was taken from rat tail veins and immediately
placed on the test strip. The blood glucose was measured by an Accu-
Chek Active blood glucose meter (Roche Diagnostics GmbH, Germany).
The maximum measurable blood glucose level that could be detected in
the applied test is 33.3 mmol/l. The animals were considered diabetic if
the blood glucose concentration was higher than 14 mmol/l.
2.5. Nociceptive test (assessment of neuropathic pain)
Mechanical allodynia was determined on the day prior to STZ
treatment and on the 3rd, 6th and 9th weeks after STZ treatment.
Brieﬂy, a metal ﬁlament with a 0.5 mm diameter was applied to the
plantar surface of the animal paw. The threshold of hind paw with-
drawal was determined using a Dynamic Plantar Aesthesiometer (DPA)
(Ugo Basile, Italy) as described previously (de Novellis et al., 2012;
Starowicz et al., 2013). Animals were placed in plastic cages with a
perforated metal platform ﬂoor for the DPA once a day for 3 days
(“handling”) before STZ treatment. Animals were kept in these cages for
at least 5 min before starting the measurement to habituate them. In-
creasing force was initiated when the tip of the metal ﬁlament touched
the plantar surface of the rat’s hind paw. The force was automatically
set, and 50 g was the cut-oﬀ. The withdrawal threshold was measured
and expressed in grams before and at the 3rd, 6th and 9th weeks after
STZ treatment. The withdrawal threshold was determined alternately in
each paw three times, and the average of the measurements was re-
corded for each animal. The animals were grouped as follows: control
(weight-matched) group (n = 8), non-diabetic (vehicle treated) and
diabetic rats (n = 11).
2.6. Tissue preparation
Frontal cortex slices were prepared from the prefrontal cortex (PFC)
as described previously (Barth et al., 2008).
Caudal spinal cord segments L5-S1 were prepared using a previously
described technique (Borbely et al., 2017; Umeda et al., 1997). Spinal
cord segments were removed and placed into ice-cold modiﬁed Krebs
solution of the following composition (mmol/l): NaCl, 113; KCl, 4.7;
CaCl2, 2.5; KH2PO4, 1.2; MgSO4, 1.2; NaHCO3, 2.5; glucose, 11.5; as-
corbic acid, 0.3; and Na2EDTA, 0.03) aerated with carbogen (95%
O2 ± 5% CO2). The spinal cord segments were isolated and cut into
400-μm slices using a Mcllwain tissue chopper. The average weight of
the PFC slices was 24.61 ± 1.21 mg, (n = 60), and the average weight
of the spinal cord slices was 10.88 ± 0.28 mg, (n = 72).
2.7. Release of [3H]noradrenaline
The slices were loaded with Levo-[7-3H]noradrenaline ([3H]NA;
5 μCi/ml, sp. activity: 14.8 Ci/mmol; NET 377, American Radiolabeled
Chemicals Inc., USA) for 45 min at 37 °C in modiﬁed Krebs solution of
above mentioned composition (mmol/l): NaCl, 113; KCl, 4.7; CaCl2,
2.5; KH2PO4, 1.2; MgSO4, 1.2; NaHCO3, 2.5; glucose, 11.5; ascorbic
acid, 0.3; and Na2EDTA, 0.03) and bubbled with carbogen. After
loading, the tissue was transferred to a microvolume (100 μl) four-
channel perfusion system (Vizi et al., 1985) to measure the release of
[3H]NA from slices at rest and in response to electric ﬁeld stimulation.
The preparations were perfused with Minipuls 3 multi-channel peri-
staltic pump (Gilson Inc., Middleton, WI, USA) at 37 °C at a rate of
0.7 ml/min for 60 min with Krebs solution and continuously bubbled
with carbogen and the eﬄuent used for washing was discarded. During
the experiment, the eﬄuent was collected in 3-min fractions, and the
radioactivity was measured. The preparations were stimulated via
platinum electrodes using a Grass S88 stimulator (Astro-Med Inc., West
Warwick, RI, USA). For PFC slices, supramaximal (20 V) ﬁeld stimuli of
2-ms pulse durations were applied at 2 Hz for 90 s (Σ 180 shocks). For
spinal cord slices, supramaximal (40 V) ﬁeld stimuli of 1-ms pulse
duration were applied at 3 Hz for 80 s (Σ 240 shocks). This type of
stimulation excited noradrenergic axons and resulted in release of NA in
a tetrodotoxine-sensitive manner (Vizi et al., 1997). The amount of the
release induced by the ﬁrst stimulation (S1) was used as an internal
standard. Local anaesthetics were applied 21 min before the second
stimulation (S2) was applied to the preparations and kept in the solution
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continuously afterwards. After the fractions were collected, 0.5 ml of
each perfusate solution was mixed with 2 ml of liquid scintillation
cocktail. The radioactivity was determined as described in the following
section.
At the end of the experiments, tissues were homogenized in 0.5 ml
of 10% trichloroacetic acid for 30 min. Aliquots (500 μl) of the super-
fusate and aliquots (100 μl) of the tissue supernatant were added to
2 ml of Packard Ultima Gold scintillation cocktail. Released [3H]NA
was counted with a Packard-Canberra TR 1900 liquid scintillation
counter, and the radioactivity was expressed as d.p.m./g tissue (Bq/g).
The fractional release (FR) was expressed as a percentage of the total
tissue tritium content at the onset of the collection period. The frac-
tional release represents the percentage of the total [3H]NA content
present at the beginning of the fraction collection period that was re-
leased from the tissue in a speciﬁc fraction. The transmitter release
collected in four fractions following electrical stimulation (fractions 3–6
and 13–16) was considered to be the release due to neuronal activity
(FRS1 and FRS2). The release in the two subsequent consecutive frac-
tions (7–8 and 17–18) was considered the resting release.
2.8. Statistical analysis
Radioactivity values corresponding to [3H]NA uptake and release
were statistically analysed using one or two-way ANOVA with
Graphpad-Prism 7.0 statistical software. The data are presented as the
means ± SEM. A p value < 0.05 was considered statistically sig-
niﬁcant.
3. Results
3.1. Streptozotocin-induced neuropathic pain in diabetic rats
The rats treated with streptozotocin became diabetic (blood glucose
level were> 14 mmol/l) (Fig. 1A) and displayed pronounced tactile
allodynia (Fig. 1B), as indicated by a signiﬁcant decrease in paw
pressure thresholds (unpaired t-test, p < 0.05). The peak of allodynia
was achieved 9 weeks after STZ treatment (Fig. 1B). The paw pressure
threshold was (g) 40.88 ± 2.74 (n = 7) for non-diabetic rats and
32.02 ± 1.95 (12) for diabetic rats.
3.2. Uptake and release of [3H]NA measured in PFC and spinal cord slices
prepared from non-diabetic and diabetic rats
In 19 experiments, the PFC slices prepared from non-diabetic rats
contained 354.90 ± 21.41 kBq/g radioactivity after 45 min of loading
with [3H]NA and subsequent washing (Table 1). Over a 3-min collec-
tion period at rest, the average release from the PFC slices was
4.02 ± 0.46 kBq/g (1.24 ± 0.14% of the total radioactive content,
n = 19). In response to electrical ﬁeld stimulation, the release (S1) was
10.87 ± 1.24 kBq/g (n = 19), which was 2.63 ± 0.29% of the
radioactivity present in the PFC tissue at the time of stimulation. When
we compared the uptake and resting release of [3H]NA measured in
non-diabetic and diabetic brain slices, a signiﬁcantly higher amount of
[3H]NA was taken up by the slices prepared from diabetic rats
(Table 1). Similarly, the release at rest was higher in diabetic pre-
parations (Table 1). However, there was no signiﬁcant diﬀerence in
stimulation-evoked releases.
After the tissue had been loaded, the average uptake of radioactivity
in the spinal cord slices from the control (non-diabetic) group was
235.0 ± 15.2 kBq/g (Table 2, n = 24), and failed to diﬀer from uptake
measured in diabetic rats (Table 2, n = 48). The average resting release
was 3.11 ± 0.18 kBq/g, 1.69 ± 0.09% of the total radioactivity
content of the tissue (FRR1) (n = 24) and was not signiﬁcantly diﬀerent
from the release measured in diabetic slices. In response to electrical
stimulation (S1), the release was 5.31 ± 0.46 kBq/g, 2.65 ± 0.18%
(n = 24) of the total radioactivity present in the slices.
3.3. Eﬀects of articaine and lidocaine on [3H]-NA release from PFC and
spinal cord slices prepared from non-diabetic and diabetic rats
The eﬀects of articaine compared to lidocaine on [3H]NA release
from PFC (Table 1) and spinal cord slices (Table 2) at various con-
centrations (0.3–10 mM) (Table 3) were studied and were likely
reached following injection into the tissue. In PFC preparations at rest,
0.7 ± 0.05% of the radioactive content was released during the 3-min
collection period. The change in resting release over a 30-min period
was always compared to the control value (FRR1), determined during
Fig. 1. Eﬀects of streptozotocin treatment on blood
glucose level and nociceptive test (for details, see
Materials and Methods).
(A) Blood glucose level: non-diabetic rats
(6.57 ± 0.37 mmol/l, n = 6) and diabetic rats
(22.03 ± 2.31 mmol/l, n = 12). The diﬀerence is
signiﬁcant, p = 0.003, unpaired t-test. (B)
Assessment of neuropathic pain measured by
Dynamic Plantar Aesthesiometer and expressed as
paw threshold (g). Vertical lines show SEM.
Table 1
The uptake and release (at rest and stimulation-evoked) of [3H]NA from PFC slices pre-
pared from non-diabetic and diabetic rats.
Non-diabetic Diabetic Signiﬁcance
Uptake (kBq/g) 354.90 ± 21.41 439 ± 28.23 p < 0.05
n = 19 n = 41
R1 resting release (kBq/g) 4.02 ± 0.46 5.38 ± 0.30 p < 0.05
n = 19 n = 41
S1 stimulation-evoked release
(kBq/g)
10.87 ± 1.24 13.19 ± 1.04 n.s.
n = 19 n = 41
Stimulation: 2 Hz, 2 ms impulse duration, 20 V supramaximal ﬁeld stimuli for 90 s, Σ 180
shocks. Two-tailed Welch corrected t-test. The stimulation-evoked release of [3H]NA was
expressed in kBq/g measured on the top of resting release.
Table 2
The uptake and release (resting and stimulation-evoked) of [3H]NA from spinal cord
slices prepared from non-diabetic and diabetic rats.
Non-diabetic Diabetic Signiﬁcance
Uptake (kBq/g) 235.0 ± 15.17 261.4 ± 13.36 n.s.
n = 24 n = 48
R1 resting release (kBq/g) 3.11 ± 0.18 3.55 ± 0.17 n.s.
n = 24 n = 24
S1 evoked release (kBq/g) 5.31 ± 0.46 5.00 ± 0.28 n.s.
n = 24 n = 24
Stimulation: 3 Hz, 1 ms impulse duration, 40 V supramaximal ﬁeld stimuli for 80 s, Σ 240
shocks. Two-tailed Welch corrected t-test. The stimulation-evoked release of [3H]NA was
expressed in kBq/g measured on the top of resting release.
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the 3-min collection period (FRR2/FRR1 = 0.87 ± 0.06, n = 6)
(Fig. 2A). In samples that underwent electrical ﬁeld stimulation, [3H]
NA was released (S1 = 7.4 ± 0.9 kBq/g, n = 6), and the FRS2/FRS1
was 0.84 ± 0.09 (n = 6). At a concentration of 3 mM, articaine re-
sulted in a four-fold increase in the resting release (Fig. 2C), whereas
lidocaine resulted in a two and a half-fold (Fig. 2B) increase. While
3 mM articaine completely blocked the stimulation-evoked release
(Fig. 2C), lidocaine only reduced this release. However, 10 mM of li-
docaine completely blocked the stimulation-evoked release and en-
hanced the resting release by more than ﬁve times (Table 3). Articaine
at the 0.3 mM concentration induced a signiﬁcant 1.4-fold increase in
resting release and failed to reduce the stimulation-evoked release. No
diﬀerences were observed in the eﬀects of local anaesthetics on the
resting release measured in non-diabetic and diabetic slices; both con-
ditions enhanced the release to the same extent (Table 2).
In spinal cord slices, both lidocaine and articaine signiﬁcantly in-
creased the resting release (Table 2, Fig. 2B and C, E and F), and their
eﬀects on the release of NA from slices prepared from non-diabetic and
diabetic animals diﬀered.
4. Discussion
In dental care and during spinal and epidural anaesthesia, the
neurons are exposed to relatively high concentrations of local anaes-
thetics that diﬀuse directly into the tissue (Strichartz, 2010) and beside
their therapeutical action may cause adverse eﬀects. Since a signiﬁcant
proportion of diabetic patients have clinical or subclinical neuropathy,
there may be concerns about the use of local anaesthetics. For epidural
anaesthesia and in dental care, local anaesthetics are applied at con-
centrations of 1.5–2% (lidocaine, 55.2-69.25 mM) or 1–4% (articaine,
31.41–124.67 mM) for dental analgesia (Haase et al., 2008). Therefore,
the present study was designed to determine and compare the eﬀects of
articaine and lidocaine on the resting and axonal stimulation-evoked
release of [3H]NA in prefrontal cortex and spinal cord slices prepared
from non-diabetic and streptozotocin-induced diabetic rats. We failed
to observe diﬀerences between the axonal stimulation-evoked releases
measured in slices obtained from non-diabetic and diabetic rats. These
ﬁndings indicate that there is no impairment in nerve conduction. The
uptake and resting release of NA were higher in brain slices prepared
from diabetic rats but not in preparations obtained from the spinal cord.
Any inhibitory eﬀect of local anaesthetics on the release of transmitter
Table 3
Eﬀects of articaine and lidocaine on stimulation-evoked and resting release of [3H]NA from cortex slice preparations of non-diabetic rats.
Concentrations FRS2/FRS1 Signiﬁcance FRR2/FRR1 Signiﬁcance
Control 0.84 ± 0.09 (6) 0.87 ± 0.06 (6)
Articaine 0.3 mM 1.22 ± 0.10 (6) n.s. 1.40 ± 0.08 (6) n.s.
3 mM 0,02 ± 0.11 (7) p < 0.01 3.89 ± 0.46 (7) p < 0.05
10 mM release fully inhibited – 13,49 ± 0.77 (4) p < 0.01
Lidocaine 0.3 mM 1.00 ± 0.05 (6) n.s. 0.79 ± 0.02 (6) n.s.
3 mM 0,41 ± 0.23 (6) n.s. 2,46 ± 0.27 (6) n.s.
10 mM 0,01 ± 0.01 (6) p < 0.01 4,62 ± 0.01 (6) n.s.
Fig. 2. Eﬀects of lidocaine (B and E) and articaine (C and F) on the fractional release of [3H]noradrenaline (FR% of [3H]NA) in prefrontal cortex slices prepared from non-diabetic (A,B,C)
and diabetic (D,E,F) rats. A and D show control experiments (n = 6). The slices were stimulated twice (S1 and S2), as indicated. Vertical lines represent the SEM. FR, fractional release
(n = 6-6). Administration of local anaesthetics are indicated. The resting releases in the 2nd (R1) and 13th (R2) collection periods were compared for signiﬁcance. The release of [3H]NA
was increased by both local anaesthetics in non-diabetic and diabetic preparations and was highly signiﬁcant, (p< 0.05). For PFC slices, supramaximal (20 V) ﬁeld stimuli of 2-ms pulse
durations were applied at 2 Hz for 90 s (∑ 180 shocks).
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from nerve terminals in response to axonal activity or an increase in
release at rest (deﬁned as when there is no axonal ﬁring) indicates a
Na+-channel- or K+-channel-dependent action. The former eﬀect re-
sults in conduction blockage and numbing of pain, and the latter eﬀect
may produce adverse reactions.
It should be mentioned that in clinical studies investigating local
anaesthetics, an increased duration of sensory block in diabetic vs
control patients was observed (Echevarria et al., 2008). These ﬁndings
are consistent with the results observed in rats (Kalichman and Calcutt,
1992; Kroin et al., 2012). When the therapeutic eﬃcacy of articaine was
compared (Snoeck, 2012) to that of other local anaesthetics (lidocaine,
prilocaine and chloroprocaine), the studies failed to show any evidence
of clinical advantages of any anaesthetic over another.
Our ﬁndings with articaine and lidocaine administered at con-
centrations of 0.3–3 mM were that the stimulation-evoked releases
were inhibited in a concentration-dependent manner, with the resting
release increasing by two to six times (Table 3), depending on the
concentration applied. This indicated the inhibitory action of these
anaesthetics on Na+- and K+-channels (Fig. 3A–D). In clinical practice,
these concentrations were easily reached and could inhibit both the
Na+ and K+ channels. As far as adverse eﬀects are concerned, the ef-
fects on K+ channels seem to be more important. The inhibitory eﬀects
on K+ channels result in the release of large amounts of transmitters,
including NA and glutamate, into the extracellular space, where their
metabolites (DOPAL and DOPEGAL) (Burke et al., 2004) and glutamate
itself could be neurotoxic. In this respect, articaine has a thiophene ring
with high lipid solubility (Snoeck, 2012), which may confer a potential
risk for some patients. Neurotoxic injuries have been reported after
local anesthetics, in humans even an overrepresentation of neurosen-
sory disturbance associated with 4% formulations of articaine used in
dentistry (Garisto et al., 2010). In addition a concentration-dependent
neurotoxicity was show in animal experiments after 4% rather than 2%
of articaine (Hillerup et al., 2011). However, articaine does display an
advantage of negligible cardiotoxic eﬀects compared to other local
anaesthetics (Szabo et al., 2007).
The intrathecal and epidural administration of α2-adrenoceptor
agonists (e.g. clonidine) are widely used for spinal analgesia for in-
trectable pain (Rauck et al., 1993). Accordingly, the NA-releasing eﬀect
of anesthetics (lidocaine and bupivacaine, (Borbely et al., 2017; Sircuta
et al., 2016) and articaine (this paper) may be involved in their pain
killing eﬀects.
Epidural infusion of local anesthetic alone may be applied for
postoperative analgesia. It has been shown, that articaine (50 mg) used
for spinal anesthesia (Bachmann et al., 2012a) for knee arthroscopy
(Hendriks et al., 2009) migh result in more than 2 mM concentration in
lumbo sacral cerebrospinal ﬂuid (∼60 ml). In our experiments articaine
(inhibited NA release in response to ﬁeld stimulation) produces a
complete block of nerve conduction, but also results in high ambient
concentration of NA in the extraneuronal space, therefore we conclude,
that NA released by anesthetics are involved in their pain-killing eﬀects
via stimulation of α2-adrenoceptors.
Our ﬁndings may have implications for the appropriate dosages of
local anaesthetics in diabetic patients undergoing regional analgesia
with nerve blocks either in dental treatment or in spinal anaesthesia.
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Fig. 3. Eﬀect of lidocaine (B and E) and articaine (C and F) on resting and stimulation-evoked fractional release of [3H]noradrenaline (FR% of [3H]NA) in spinal cord slices prepared from
non-diabetic (A,B,C) and diabetic (D,E,F) rats. A and D show control experiments. Stimulation (S1 and S2). Vertical lines represent the SEM. The resting releases in the 2nd (R1) and 13th
(R2) collection periods were compared for signiﬁcance. The release of [3H]NA was increased by both local anaesthetics in non-diabetic and diabetic preparations and was highly
signiﬁcant, (p < 0.05). For further details, see Fig. 2. (n = 6–6). For spinal cord slices, supramaximal (40 V) ﬁeld stimuli of 1-ms pulse durations were applied at 3 Hz for 80 s (∑ 240
shocks).
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